Search
Returning search results with filters:
Remove filter for
Audience: General public
Remove filter for
Category: Drugs
Remove filter for
Issue: Product quality
Remove filter for
Type: Recall
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 15 of 98 items.
PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
REDDY-SAPROPTERIN: Affected lot recalled due to potential for unexpected colour change
RecallHealth product recall | 2024-04-17
I-131 Diagnostic Capsule: Affected lots may have decreased thyroid uptake.
RecallHealth product recall | 2024-04-17
JAMP-Guanfacine XR 4 mg: Foreign matter
RecallHealth product recall | 2024-04-10
JAMP-Rabeprazole 20 mg: Affected lot may contain JAMP-Rabeprazole 10 mg
RecallHealth product recall | 2024-04-02
JAMP CEPHALEXIN SUSPENSION: Suspendability out of specification
RecallHealth product recall | 2024-03-21
FOLIC ACID 1MG - Affected lots exceed or may exceed the acceptable intake limit for N-nitroso-folic acid.
RecallHealth product recall | 2024-03-12
JAMP TELMISARTAN-HCT: Affected lots may contain higher dosage than the labelled dose
RecallHealth product recall | 2024-01-24
PEDIATRIX ORAL SOLUTION 100mg: Out of specification
RecallHealth product recall | 2024-01-15
0.9% SODIUM CHLORIDE INJECTION, USP: Solution bags may be leaking in affected lots. (Updated with new lot numbers)
RecallHealth product recall | 2023-12-24
Bleomycin for Injection USP: Glass Particulate
RecallHealth product recall | 2023-12-21
Apo-Metoprolol 25 mg tablets: Affected lot may contain over-sized tablets
RecallHealth product recall | 2023-12-12
Taro-Dipyridamole/ASA: impurity
RecallHealth product recall | 2023-12-08
JAMP-ASA EC: out of specification
RecallHealth product recall | 2023-12-04